Lyell Immunopharma annual operating expenses
2019
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Operating Expenses Growth & History (LYEL)
Lyell Immunopharma's operating expenses was $269.4M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $269.4M | −$89.4M | −24.91% |
| 2024 | 2024-12-31 | $358.8M | $111.7M | +45.19% |
| 2023 | 2023-12-31 | $247.1M | −$24.6M | −9.05% |
| 2022 | 2022-12-31 | $271.7M | $46.3M | +20.55% |
| 2021 | 2021-12-31 | $225.4M | $5.7M | +2.61% |
| 2020 | 2020-12-31 | $219.7M | $116.9M | +113.82% |
| 2019 | 2019-12-31 | $102.7M | — | — |
Lyell Immunopharma quarterly operating expenses
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $47.3M | $193,000 | +0.41% |
| Q1 2026 | 2026-03-31 | $44.3M | −$13.1M | −22.85% |
| Q4 2025 | 2025-12-31 | $127.7M | −$73.5M | −36.54% |
| Q3 2025 | 2025-09-30 | $37.3M | −$13.3M | −26.26% |
| Q2 2025 | 2025-06-30 | $47.1M | −$4.4M | −8.52% |
| Q1 2025 | 2025-03-31 | $57.4M | $1.8M | +3.23% |
| Q4 2024 | 2024-12-31 | $201.2M | $141.6M | +237.96% |
| Q3 2024 | 2024-09-30 | $50.5M | −$8.5M | −14.43% |
| Q2 2024 | 2024-06-30 | $51.5M | −$14.4M | −21.83% |
| Q1 2024 | 2024-03-31 | $55.6M | −$7.0M | −11.25% |
| Q4 2023 | 2023-12-31 | $59.5M | −$3.6M | −5.78% |
| Q3 2023 | 2023-09-30 | $59.1M | −$7.4M | −11.10% |
| Q2 2023 | 2023-06-30 | $65.9M | −$7.1M | −9.68% |
| Q1 2023 | 2023-03-31 | $62.6M | −$6.5M | −9.41% |
| Q4 2022 | 2022-12-31 | $63.2M | $12.8M | +25.44% |
| Q3 2022 | 2022-09-30 | $66.4M | $14.5M | +27.98% |
| Q2 2022 | 2022-06-30 | $73.0M | $7.7M | +11.73% |
| Q1 2022 | 2022-03-31 | $69.1M | $11.3M | +19.57% |
| Q4 2021 | 2021-12-31 | $50.4M | — | — |
| Q3 2021 | 2021-09-30 | $51.9M | $14.0M | +36.93% |
| Q2 2021 | 2021-06-30 | $65.3M | −$40.3M | −38.18% |
| Q1 2021 | 2021-03-31 | $57.8M | — | — |
| Q3 2020 | 2020-09-30 | $37.9M | — | — |
| Q2 2020 | 2020-06-30 | $105.7M | — | — |
Lyell Immunopharma operating expenses trends
Over the last five fiscal years, Lyell Immunopharma's operating expenses increased from $219.7M to $269.4M, a change of $49.7M. The latest reported quarter, Q2 2026, shows $47.3M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗